Publikačný výstup

2022-2022: [1] KARKHANEH, Leyla - TABATABAEI-MALAZY, Ozra - BANDARIAN, Fatemeh - MOHSENI, Shahrzad - LARIJANI, Bagher. Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review. In Journal of Diabetes and Metabolic Disorders, 2022-06-01, 21, 1, pp. 863-879. Dostupné na: https://doi.org/10.1007/s40200-021-00908-x.

2022-2022: [1] LEE, Hye Ah - PARK, Hyesook - HONG, Young Sun. Sex Differences in the Effects of CDKAL1 Variants on Glycemic Control in Diabetic Patients: Findings from the Korean Genome and Epidemiology Study. In Diabetes and Metabolism Journal, 2022-11-01, 46, 6, pp. 879-889. ISSN 22336079. Dostupné na: https://doi.org/10.4093/dmj.2021.0265.

2021-2021: [1] IZAOLA-JAUREGUI, Olatz - PRIMO-MARTIN, David - JOSE LOPEZ, Juan - ANTONIO DE LUIS-ROMAN, Daniel. The risk variant of CDKAL1 (rs7756992) impairs fasting glucose levels and insulin resistance improvements after a partial meal-replacement hypocaloric diet. In ENDOCRINOLOGIA DIABETES Y NUTRICION. ISSN 2530-0180, 2021, vol. 68, no. 8, pp. 548-556. Dostupné na: https://doi.org/10.1016/j.endinu.2020.08.009. [WoS]

2021-2021: [1] LOGANADAN, Navin Kumar - HURI, Hasniza Zaman - VETHAKKAN, Shireene Ratna - HUSSEIN, Zanariah. Pharmacogenetics of sulfonylurea-induced hypoglycemia in Type 2 diabetes patients: the SUCLINGEN study. In PHARMACOGENOMICS. ISSN 1462-2416, 2021, vol. 22, no. 16, pp. 1057-1068. [WoS]

2020-2020: [1] LOGANADAN, Navin Kumar - HURI, Hasniza Zaman - VETHAKKAN, Shireene Ratna - HUSSEIN, Zanariah. Clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients: the SUCLINGEN study. In PHARMACOGENOMICS. ISSN 1462-2416, 2020, vol. 21, no. 9, pp. 587-600. [WoS]

2020-2020: [1] MITCHELL, Sabrina L. - LEON, Daniel A. Carranza - CHAUGAI, Sandip - KAWAI, Vivian K. - LEVINSON, Rebecca T. - WEI, Wei-Qi - STEIN, C. Michael. Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care. In PHARMACOGENOMICS JOURNAL. ISSN 1470-269X, 2020, vol. 20, no. 6, pp. 831-839. [WoS]

2019-2019: [1] KHATAMI, Fatemeh - MOHAJERI-TEHRANI, Mohammad R. - TAVANGAR, Seyed M. The Importance of Precision Medicine in Type 2 Diabetes Mellitus (T2DM): From Pharmacogenetic and Pharmacoepigenetic Aspects. In ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. ISSN 1871-5303, 2019, vol. 19, no. 6, pp. 719-731. Dostupné na: https://doi.org/10.2174/1871530319666190228102212. [WoS]

2019-2019: [1] LAM, Y. W. Francis - DUGGIRALA, Ravindranath - JENKINSON, Christopher P. - ARYA, Rector. The Role of Pharmacogenomics in Diabetes. In PHARMACOGENOMICS: CHALLENGES AND OPPORTUNITIES IN THERAPEUTIC IMPLEMENTATION, 2ND EDITION, 2019, vol., no., pp. 247-269. [WoS]

2018-2018: [1] PANG, Bing - ZHAO, Lin-hua - LI, Xin-long - SONG, Jun - LI, Qing-wei - LIAO, Xing - FENG, Shuo - ZHAO, Xi-yan - ZHENG, Yu-jiao - GOU, Xiao-wen - NI, Qing - TONG, Xiao-lin. Different intervention strategies for preventing type 2 diabetes mellitus in China: A systematic review and network meta-analysis of randomized controlled trials. In DIABETES OBESITY & METABOLISM. ISSN 1462-8902, 2018, vol. 20, no. 3, pp. 718-722. Dostupné na: https://doi.org/10.1111/dom.13121. [WoS]

2018-2018: [3] SOLTANI, G. - HATEFI, Z. - SALEHI, A.R. - KHOSRAVI, S. - GHIASI, M.R. - TEKE, K. - AMINORROAYA, A. - SALEHI, R. Pharmacogenomics of Sulfonylureas Response in Relation to rs7754840 Polymorphisms in Cyclin-Dependent Kinase 5 Regulatory Subunit-associated Protein 1-like (CDKAL1) Gene in Iranian Type 2 Diabetes Patients. In Advanced biomedical research. ISSN 2277-9175, 2018, vol. 7, p. 1-4.

2016-2016: [1] LOGANADAN, N. K. - HURI, H. Z. - VETHAKKAN, S. R. - HUSSEIN, Z. Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation. In PHARMACOGENOMICS JOURNAL. ISSN 1470-269X, 2016, vol. 16, no. 3, pp. 209-219. Dostupné na: https://doi.org/10.1038/tpj.2015.95. [WoS]

2016-2016: [1] OSADA, Uru Nezu - SUNAGAWA, Hiroshi - TERAUCHI, Yasuo - UEDA, Shinichiro. A Common Susceptibility Gene for Type 2 Diabetes Is Associated with Drug Response to a DPP-4 Inhibitor: Pharmacogenomic Cohort in Okinawa Japan. In PLOS ONE. ISSN 1932-6203, 2016, vol. 11, no. 5, pp. Dostupné na: https://doi.org/10.1371/journal.pone.0154821. [WoS]

2015-2015: [1] LIANG, Jun - PEI, Ying - LIU, Xuekui - QIU, Qinqin - SUN, Yuting - ZHU, Yan - YANG, Manqing - QI, Lu. The CDKAL1 gene is associated with impaired insulin secretion and glucose-related traits: the Cardiometabolic Risk in Chinese (CRC) study. In CLINICAL ENDOCRINOLOGY. ISSN 0300-0664, 2015, vol. 83, no. 5, pp. 651-655. Dostupné na: https://doi.org/10.1111/cen.12838. [WoS]

2014-2014: [1] KAVVOURA, F. K. - PAPPA, M. - EVANGELOU, E. - NTZANI, E. E. The Genetic Architecture of Type 2 Diabetes Pharmacotherapy: The Emerging Genomic Evidence. In CURRENT PHARMACEUTICAL DESIGN. ISSN 1381-6128, 2014, vol. 20, no. 22, pp. 3610-3619. [WoS]

2014-2014: [1] SARIN, L. Peter - LEIDEL, Sebastian A. Modify or die? RNA modification defects in metazoans. In RNA BIOLOGY. ISSN 1547-6286, 2014, vol. 11, no. 12, pp. 1555-1567. Dostupné na: https://doi.org/10.4161/15476286.2014.992279. [WoS]

2013-2013: [1] AQUILANTE, Christina L. - LAM, Y. W. Francis. The Role of Pharmacogenomics in Diabetes, HIV Infection, and Pain Management. In PHARMACOGENOMICS: CHALLENGES AND OPPORTUNITIES IN THERAPEUTIC IMPLEMENTATION, 2013, vol., no., pp. 247-271. Dostupné na: https://doi.org/10.1016/B978-0-12-391918-2.00007-X. [WoS]

2012-2012: [1] MANNINO, Gaia Chiara - SESTI, Giorgio. Individualized Therapy for Type 2 Diabetes Clinical Implications of Pharmacogenetic Data. In MOLECULAR DIAGNOSIS & THERAPY. ISSN 1177-1062, 2012, vol. 16, no. 5, pp. 285-302. Dostupné na: https://doi.org/10.1007/s40291-012-0002-7. [WoS]